ADVERSE EVENTS ASSOCIATED WITH mTOR INHIBITION: RESULTS FROM THE A2310 STUDY COMPARING EVEROLIMUS AND MMF IN DE NOVO HEART TRANSPLANT RECIPIENTS

被引：0
|
作者：
Poncelet, A. [1 ]
Musumeci, F. [2 ]
Fuchs, U. [3 ]
Mattei, M. F. [4 ]
Dong, G. [5 ]
Lopez, P. [6 ]
Hirt, S. [7 ]
机构：
[1] Catholic Univ Louvain, Fac Med, B-1200 Brussels, Belgium
[2] S Camillo Forlanini Hosp, Dept Cardiovasc Sci, Rome, Italy
[3] Ruhr Univ Bochum, Heart Ctr N Rhine Westphalia, Univ Hosp, Bad Oeynhausen, Germany
[4] Hop Brabois, Dept Cardiol & Transplantat, Nancy, France
[5] Novartis Pharmaceut, Dev, E Hanover, NJ USA
[6] Novartis Pharma AG, Clin Dev, Basel, Switzerland
[7] Univ Med Ctr Regensburg, Dept Cardiothorac Surg, Regensburg, Germany
来源：
TRANSPLANT INTERNATIONAL | 2011年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [41] Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients
    Lehmkuhl, Hans B.
    Mai, Daniel
    Dandel, Michael
    Knosalla, Christoph
    Hiemann, Nicola E.
    Grauhan, Onnen
    Huebler, Michael
    Pasic, Miralem
    Weng, Yuguo
    Meyer, Rudolph
    Rothenburger, Markus
    Hummel, Manfred
    Hetzer, Roland
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (07): : 700 - 704
  • [42] Safety of Early Everolimus in De Novo Heart Transplant Recipients: Interim Analysis of the Randomized Study EVERHEART.
    Potena, L.
    Barberini, F.
    Boffini, M.
    Maiello, C.
    Pedrazzini, G.
    Faggian, G.
    Gerosa, G.
    Lilla, P.
    Marraudino, N.
    Corda, M.
    Bernazzali, S.
    Guarisco, R.
    Livi, U.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 93 - 93
  • [43] CMV Infections Are Less Frequent in De Novo Heart Transplant Recipients Receiving Immunosuppression with Everolimus Plus Reduced CsA Compared to MMF and Standard CsA
    Kobashigawa, J.
    Ross, H.
    Kfoury, A. G.
    Van Bakel, A.
    Ewald, G.
    Burton, J.
    Andreassen, A.
    Banchs, H. L.
    Segovia, J.
    Lopez, P.
    Cines, M.
    Dong, G.
    Potena, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 131 - 132
  • [44] CMV INFECTIONS ARE LESS FREQUENT IN DE NOVO HEART TRANSPLANT RECIPIENTS RECEIVING IMMUNOSUPPRESSION WITH EVEROLIMUS PLUS REDUCED CSA COMPARED TO MMF AND STANDARD CSA
    Schulz, U.
    Kobashigawa, J.
    Bara, C.
    Hirt, S.
    Lehmkuhl, H. B.
    Lopez, P.
    Costard-Jaeckle, A.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 22 - 22
  • [45] Incidence of CMV infection with concentration-controlled everolimus or MMF:: 12-month results from a randomized trial in de novo heart transplant patients
    Pellegrini, Carlo
    Dengler, Thomas
    Branzi, Angelo
    Guillemain, Romain
    Varnous, Shaida
    Gerosa, Gino
    Poncelet, Alain
    Vanhaecke, Johan
    Li, Yulan
    Gezahegen, Yonas
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 571 - 571
  • [46] Efficacy and Safety of Everolimus with Reduced-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Results from the TRANSFORM Study
    Pascual, Julio
    Chadban, Steve
    Tedesco, Helio
    Berger, Stefan
    Qazi, Yasir
    Cruzado, Josep M.
    Bernhardt, Peter
    Legendre, Christophe
    Kim, Myoung Soo
    Vincenti, Flavio
    TRANSPLANTATION, 2018, 102 : S367 - S368
  • [47] Class Related Adverse Events in Renal Transplant Recipients Treated with Everolimus: 24 Month Results from the A2309 Study.
    Walker, R.
    Vathsala, A.
    Zibari, G. B.
    Kim, Y. S.
    Cibrik, D.
    Johnston, T.
    Cornu-Artis, C.
    Panis, C.
    Wang, Z.
    Tedesco-Silva, H.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 407 - 407
  • [48] Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses
    Miranda, Tamiris A.
    Felipe, Claudia R.
    Santos, Renato H. N.
    Pestana, Jose O. Medina
    Tedesco-Silva Junior, Helio
    THERAPEUTIC DRUG MONITORING, 2020, 42 (06) : 811 - 820
  • [49] Everolimus and reduced-exposure cyclosporine vs mmf and standard-expsosure cyclosporine:: 12-month results in DE NOVO cardiac transplant recipients
    Livi, Ugolino
    Lehmkuhl, Hans
    Arizon, Jose
    Vigano, Mario
    Magelli, Carlo
    Boissonnat, Pascale
    Gerosa, Gino
    Musumeci, Francesco
    Gandjbakhch, Iradj
    Vanhaecke, Johan
    Abeywickrama, Kamal
    TRANSPLANT INTERNATIONAL, 2007, 20 : 93 - 94
  • [50] SNPs Within the MTOR Gene Are Associated With an Increased Risk of Developing De Novo Diabetes Mellitus Following the Administration of Everolimus in Liver Transplant Recipients
    Husen, Peri
    Straub, Katja
    Willuweit, Katharina
    Hagemann, Anna
    Wedemeyer, Heiner
    Bachmann, Hagen S.
    Herzer, Kerstin
    TRANSPLANTATION PROCEEDINGS, 2019, 51 (06) : 1962 - 1971
12345